These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30405853)

  • 21. Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.
    Steendam CMJ; Atmodimedjo P; de Jonge E; Paats MS; van der Leest C; Oomen-de Hoop E; Jansen MPHM; Del Re M; von der Thüsen JH; Dinjens WNM; van Schaik RHN; Aerts JGJV; Dubbink HJ;
    JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis.
    Helmijr J; Motta G; Jongbloed L; de Weerd V; van Bergen L; Verschoor N; Stella S; Beaufort C; Vigneri P; Martens JWM; Wilting SM; Jansen MPHM
    J Appl Lab Med; 2024 Sep; 9(5):913-925. PubMed ID: 39012846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.
    Giménez-Capitán A; Bracht J; García JJ; Jordana-Ariza N; García B; Garzón M; Mayo-de-Las-Casas C; Viteri-Ramirez S; Martinez-Bueno A; Aguilar A; Sullivan IG; Johnson E; Huang CY; Gerlach JL; Warren S; Beechem JM; Teixidó C; Rosell R; Reguart N; Molina-Vila MA
    Clin Chem; 2021 Mar; 67(3):554-563. PubMed ID: 33439966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
    Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
    Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell free DNA analysis by SiRe
    Pisapia P; Pepe F; Smeraglio R; Russo M; Rocco D; Sgariglia R; Nacchio M; De Luca C; Vigliar E; Bellevicine C; Troncone G; Malapelle U
    J Thorac Dis; 2017 Oct; 9(Suppl 13):S1383-S1390. PubMed ID: 29184677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants.
    Chai SY; Peng R; Zhang R; Zhou L; Pillay N; Tay KH; Badrick T; Li J; Horan MP
    Pathol Oncol Res; 2020 Jul; 26(3):1595-1603. PubMed ID: 31487000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 34. Detection of KRAS mutations in plasma cell-free DNA of colorectal cancer patients and comparison with cancer panel data for tissue samples of the same cancers.
    Min S; Shin S; Chung YJ
    Genomics Inform; 2019 Dec; 17(4):e42. PubMed ID: 31896242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and characterization of reference materials for EGFR, KRAS, NRAS, BRAF, PIK3CA, ALK, and MET genetic testing.
    Zhang W; Qu S; Chen Q; Yang X; Yu J; Zeng S; Chu Y; Zou H; Zhang Z; Wang X; Jing R; Wu Y; Liu Z; Xu R; Wu C; Huang C; Huang J
    Technol Health Care; 2023; 31(2):485-495. PubMed ID: 36093718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.
    Sherwood JL; Brown H; Rettino A; Schreieck A; Clark G; Claes B; Agrawal B; Chaston R; Kong BSG; Choppa P; Nygren AOH; Deras IL; Kohlmann A
    ESMO Open; 2017; 2(4):e000235. PubMed ID: 29018576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
    Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
    Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.
    Weber S; Spiegl B; Perakis SO; Ulz CM; Abuja PM; Kashofer K; Leest PV; Azpurua MA; Tamminga M; Brudzewsky D; Rothwell DG; Mohan S; Sartori A; Lampignano R; Konigshofer Y; Sprenger-Haussels M; Wikman H; Bergheim IR; Kloten V; Schuuring E; Speicher MR; Heitzer E
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32560092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.